Objective: The established link between oestrogen and breast cancer occurs via both oestrogen receptor (ER)-mediated and non ER-mediated mechanisms. The term genotoxic estrogens describes mutagenic metabolites, including oestrogen catechols and quinones, which have been linked to breast carcinogenesis in post-menopausal women. We aimed to assess whether the route of administration of 17β oestradiol (E 2 ) affects the accumulation of genotoxic oestrogen metabolites in a model of ovarian failure in young girls with Turner syndrome.
| BACKG ROU N D
When replacing oestrogen in young women with hypogonadism, the type, dose and mode of administration of oestrogen can impact oestrogen's biological effects and potentially their relative safety. Girls with Turner syndrome have premature ovarian failure and need oestrogen for feminization in puberty; hence, they are a unique model to study the impact of oestrogen in biological systems in vivo. We administered the same oestrogen, 17β oestradiol (E 2 ) either orally or transdermally to a group of 40 girls with primary gonadal failure due to Turner syndrome, 1 groups matched for unconjugated E 2 levels. We observed no significant differences between groups in body composition, fat free mass accrual, % fat mass, bone mineral density, plasma lipids and an array of metabolic indices after 12 months of treatment. However, there was a considerable difference in the accumulation of metabolites of oestrogen (E 1 and E 1 sulphate) and in total oestrogenic activity, as measured by a recombinant cell bioassay, with concentrations of all being higher in the oral group. 1 This information was concerning, as an increasing body of data has accumulated in the last decade suggesting that oral, but not transdermal oestrogen delivery is associated with a greater thromboembolic risk, including increased risk of strokes and cardiovascular events. [2] [3] [4] [5] [6] These findings suggest that thrombotic risk from oestrogen exposure is directly associated with the first passage of oral oestrogens through the portal circulation, increasing hepatic exposure to oestrogens. These studies linking oestrogen to increased thromboembolic risk, however, have been mostly in post-menopausal women and not directly in adolescent patients with Turner syndrome; hence, further research is needed. Nonetheless, these cumulative data informed the conclusions in the newly released international consensus guidelines in the management of girls and women with Turner syndrome to suggest the preferred use of transdermal oestradiol, when feminizing these girls and young women.
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There is also a well-established mechanistic link between oestrogen and breast cancer carcinogenesis. Post-menopausal hormone therapy, early menarche, late menopause and circulating oestrogen levels have all been associated with a higher breast cancer risk. 8, 9 Both oestrogen receptor (ER)-mediated increased cell proliferation and ER-independent effects of oestradiol metabolites 9 may confer this increased risk. Two pathways have been proposed as the mechanisms for carcinogenesis: (a) formation of reactive oxygen species and resultant DNA damage and mutations and (b) depurination of DNA and mutations resulting from error prone DNA repair. With the first mechanism, quinones are formed from catechol-oestrogens which are back-converted to 4-OH oestrogens via quinone reductase, thus creating a redox cycle and the generation of reactive oxygen species. Via the second mechanism, the quinones bind covalently with adenine and guanine on the DNA backbone to form adenine-oestrogen and guanine-oestrogen adducts which are unstable and are cleaved causing depurination of the DNA backbone.
10-12
Genotoxic estrogens is a term used to describe these mutagenic and potentially carcinogenic oestrogen metabolites. 9, [13] [14] [15] [16] [17] The principal product of the intact gonad, 17β E 2 , is metabolized via hydroxylation at the 2, 4 and 16 positions to form 2-hydroxy oestradiol (2-OH-E 2 ), 4-hydroxy oestradiol (4-OH-E 2 ) and 16α-hydroxy oestradiol (16α-OH-E 2 ), respectively, also known as catechol derivatives. The 4-OH-E 2 is mutagenic in rat and human cells 13, 14 and associated with endometrial cancer in vivo. 15 16α-OH-E 2 has also been associated with breast cancer, but its role has been much debated. 18 These 2-and 4-catechol-oestrogens are further metabolized to their detoxified derivatives 2-methoxy (MeO)-3-hydroxy-17β-oestradiol (2-MeO-E 2 ) and 4-MeO-E 2 (Supporting Information Figure S1 ).
Oestrone (E 1 ), in addition to generating catechol derivatives, also undergoes metabolism to 16α-hydroxy-oestrone (16α-OH-E 1 ), a compound thought to be involved in tumour proliferation due to its genotoxic effects 19 and through constitutive activation of the ER [20] [21] [22] (Supporting Information Figure S2 ).
We previously reported our experience in quantifying these oestrogen metabolites in a group of lean and obese prepubertal girls using highly sensitive stable isotope dilution liquid chromatography-selected reaction monitoring/mass spectrometry (LC-MS/MS) assays. 23 These sophisticated techniques make it now possible to quantify much lower concentrations of these metabolites than previously possible. 16, 24 Using these assays, we have now performed a secondary analysis of the impact of administration of the same oestradiol (17βE 2 ) given orally vs transdermally for one year on the accumulation of genotoxic metabolites in young adolescent girls with Turner syndrome. Stored plasma on 48 normally menstruating pubertal girls, both lean and obese, sampled in the late follicular phase of the menstrual cycle were used for comparison. 26 The obese girls were otherwise healthy, with normal blood pressure, normal glucose tolerance and plasma lipids.
| ME THODS

| Study design
In brief, subjects with Turner syndrome were randomized to take either 17βE 2 orally (Estrace®; Bristol-Myers Squibb, New York, NY) or 17βE 2 transdermally (TD; Vivelle TD® system; Novartis Pharmaceuticals, East Hanover, NJ). Doses were titrated using an LCMSMS assay that measures the common unconjugated oestrogens in the laboratory of Ravinder Singh at Mayo Clinic (Rochester, MN). We achieved unconjugated E 2 levels comparable to those of normally menstruating healthy adolescents (concentrations averaged to ~100 pg/mL). 1, 25 Average maximal E 2 doses were 2 mg orally and 100 µg TD delivered daily for 21 days; progesterone (Provera® 10 mg) was added orally for the last 7 of the 21 days to cause withdrawal bleeding every 28 days. Stored samples were obtained, aliquoted and frozen at baseline (0 months) and at the end of the dosing period after treatment (12 months) until analysis. Stored plasma from 48 normally menstruating girls who participated in a previously reported study 26 was assayed similarly for the sensitive 12 oestrogen panel measuring total concentrations; their data are presented as comparison.
All study subjects in the Turner syndrome and the normally menstruating, non Turner syndrome group had anthropometric measurements using a Harpenden stadiometer and a digital scale. Body composition was measured by dual X-ray absorptiometry (DXA).
Percentage fat mass (%FM) and BMI (kg/m 2 ) were used as co-variates in the analysis.
| Assays
De-identified samples were shipped frozen to the laboratory of Dr I. Blair (University of Pennsylvania), who has developed a state-ofthe-art LC-MS/MS assay to quantify oestrogen metabolites with remarkable sensitivity, as previously described. 16 
| Statistical analysis
Laboratory staff was blinded to the individual route of oestrogen assigned in the Turner syndrome cohort; hence, data were unblinded and sorted after assay results and grouped by treatment for analysis.
Descriptive statistics were used for all demographic variables, expressed as mean ± SE. Marginal (least square) means were calculated for all oestrogen metabolite concentrations, adjusted for baseline values, as well as BMI and % fat mass. We chose % fat mass as in very short individuals (like Turner syndrome) BMI may be an inaccurate measure of adiposity. Of note, we are also expressing the data in this paper as least square means, whereas in the first report data are expressed as means. 
| RE SULTS
Groups with Turner syndrome were well-matched for age:
(mean ± SE) 16.7 ± 1.7 years, 16.7 ± 1.8, and BMI: 25.7 ± 5.9 kg/ The per cent fat mass in the non Turner syndrome comparison group was 21.9 ± 1.0% and 40.5 ± 0.9% in the lean and obese group, respectively (33.1 ± 1.5% overall).
Baseline concentrations of oestrogen metabolites were low in both oral and transdermal groups as expected since they have primary ovarian failure (data not shown). Table 1 shows the least square 
Levels of lean and obese normally menstruating girls without
Turner syndrome were similar; hence, data were grouped for analysis. Normally menstruating subjects had lower levels of all analytes, All comparisons per oestrogen compound between oral and transdermal levels, P < 0.0001. Levels measured in the non Turner syndrome controls are presented for comparison except 4-MeO-E 2 which is expressed as a regular mean concentration (Table 1) . Single factor ANOVA was performed comparing E 2 and E 1 concentrations among the oral and transdermal groups at 12 months, and healthy age-matched controls, P value was highly significant (3.75E-08 for E 2 , 2.96E-09 for E 1 ). Post hoc comparisons showed highly significant differences between oral and controls for both E 2 and E 1 (P < 0.00001), but not between transdermal and controls (P = 1.0 both E 2 and E 1 ).
| D ISCUSS I ON
Using highly sensitive tandem liquid chromatography assays, we are now able to assess differences in oestradiol metabolites in plasma with markedly enhanced sensitivity. We have observed significant differences in the accumulation of the parent compounds E 2 and E 1 after the oral route compared to transdermal, leading to tremendous accumulation of 4-OH and 2-OH-catechol E 2 and E 1 concentrations, as well as much greater concentrations of 16α-
OH-E 1 after 12 months of oral vs TD oestradiol administration.
These metabolites are considered to be potentially mutagenic in mammary tissue and associated with greater breast cancer risk. [10] [11] [12] 14, 17 These levels are also markedly higher than those of normally menstruating females whose plasma was analysed using the same assay.
As expected, the total concentrations of the parent compounds (conjugated and unconjugated), E 2 and E 1 measured after sulphatase and glucuronidase cleavage using this assay are much higher than when measured using a different LCMSMS assay reported previously 1 which measures only unconjugated oestrogens. 1, 27 These levels trended higher, but not significantly different than controls in those treated using the transdermal preparation, and levels after transdermal were much lower than the oral route. Glucuronidation of steroids happens in many extrahepatic tissues, including the skin, but orally administered oestradiol is far more extensively conjugated in the body. These results are different than those we obtained in our parent study where the concentrations of unconjugated oestradiol achieved were comparable after oral or transdermal oestradiol compared to controls. This bioassay detected much higher concentrations of bioestrogens after oral vs transdermal oestradiol administration, 1 supporting the concept that these metabolites are at least in part biologically active.
Actually using that bioassay, 65% of the levels in the oral group were much greater than the upper limits of detection of the assay and hence greater than those in normally menstruating controls. 1 The present results are remarkable, as the doses of oestradiol used are customary in the treatment of young women with many forms of hypogonadism, including Turner syndrome.
It is well-established that oestrogens contribute to carcinogenesis through complex mechanisms, and the available evidence suggests that cell proliferation and apoptosis in mammary tissue are affected via ER-mediated genomic and non-genomic signalling effects, but also via genotoxic oestrogen metabolites. 18, 19 It has been proposed that ER signalling converges to suppress effective DNA repair and apoptosis in favour of proliferation, which in turn could affect processing of oestrogen-induced DNA damage and other genotoxic insults. 28 The relative risk of breast cancer increased with each quintile of plasma oestradiol in post-menopausal women. 8, 28 Available data suggest three oestrogen-related factors that may contribute to breast cancer pathogenesis in women post menopause: 30 These data are congruent with our previously reported findings of increased levels of 16α-OH-E 1 metabolites in obese prepubertal girls. 23 In contrast, because of the rapidly changing oestrogen milieu, the levels in pubertal girls are far more variable than in prepubertal girls, making it difficult to pick up the differences in endogenous concentrations depending on adiposity as compared to girls prior to any gonadal activation.
Ever being overweight in childhood increases the risk of all cause and breast cancer death later in life, 31 suggesting that there are critical developmental periods when exposure to environmental factors, including genotoxic oestrogen metabolites, could significantly affect the impact of mammary cancers later in life.
31
Oestrogen given as physiologic replacement in hypogonadal girls and women is critically important for a plethora of beneficial metabolic effects, not only for mammary and female organs normal growth, but also beneficial for plasma lipids, cardiovascular health and bone, among others. 7, 32 Hence, the route of administration be- The use of oral contraceptives and the association with risk of mammary tumours have been difficult to establish. This is due in part to the great variability of formulations and duration of treatment, as well as existing co-morbidities of the users (eg, obesity, smoking). A systematic review of the use of oral contraceptives and breast cancer showed that incidence was slightly but significantly increased in users vs non users, 34 and a recent report in 1.8 million women in
Denmark followed longitudinally has shown that breast cancer risk is indeed higher among hormonal contraceptives users than non users, and the risk increases with duration of use. 35 Considering the fact that ~16% of women between 15 and 44 years of age in the US are on oral contraceptives (~9.7 million women) at any given time 36 and that ~1.5 million are on oestrogen compounds for non-reproductive reasons, 37 further study of the concentrations of these genotoxic oestrogenic metabolites in women using these products long-term is important, and now possible.
In conclusion, oral administration of adequate feminizing doses of the same oestradiol as that produced by the ovary, 17βE 2 , to girls with Turner syndrome results in disproportionate, significant accumulation of unphysiologic genotoxic oestrogen metabolites, compared to transdermal use. This expands the concern about oral oestrogens' first passage by the liver, not only potentially increasing thromboembolic risk, but also the risk of genotoxicity. Further studies are needed to better assess the concentrations of these metabolites in a large population of oral oestrogen users, examine their long-term risk, and whether this risk begins in adolescence.
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